Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Pre-Market Review: Star Scientific Inc., Pharmacyclics Inc., United Therapeutics Corp., and Impax Laboratories Inc.



     Pre-Market Review: Star Scientific Inc., Pharmacyclics Inc., United
               Therapeutics Corp., and Impax Laboratories Inc.

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

LONDON, November 21, 2013

LONDON, November 21, 2013 /PRNewswire/ --

On Wednesday, November 20, 2013, the S&P 500 ended the day at 1,781.37, down
0.36%; the Dow Jones Industrial Average closed at 15,900.82, down 0.41%; and
the NASDAQ Composite finished at 3,921.27, down 0.26%. Shares in
healthcare-drug makers mostly ended on a lower note, as the broader market
posted losses. The major movers in the industry included Star Scientific Inc.
(NASDAQ: STSI), Pharmacyclics Inc. (NASDAQ: PCYC), United Therapeutics
Corporation (NASDAQ: UTHR), and Impax Laboratories Inc. (NASDAQ: IPXL).
AAAResearchReports.com initiated preliminary technical research on STSI, PCYC,
UTHR, and IPXL. These free reports are accessible by signing today at:

http://www.aaaresearchreports.com/register/  

Star Scientific Inc.'s stock plummeted on Wednesday, as the broader posted
losses. The company's shares oscillated between $1.22 and $1.39 before ending
Wednesday's session 4.48% lower at $1.28. A total of 2.18 million shares were
traded, which is above the daily average volume of 0.96 million. The company's
shares have declined by 13.51% in the previous three trading sessions,
compared to a loss of 0.93% in the S&P 500 during the same period.
Furthermore, Star Scientific Inc.'s stock is trading below its 50-day and
200-day moving averages of $1.87 and $1.72, respectively. The free technical
analysis on STSI is available by signing up at:

http://www.AAAResearchReports.com/STSI112113.pdf

On Wednesday, Pharmacyclics Inc.'s stock finished at $123.54, down 0.72% from
the previous day's closing price of $124.43. The company's shares vacillated
between $122.65 and $126.88 during the trading session. A total of 0.47
million shares were traded, which is below the daily average volume of 0.82
million. Despite Wednesday's losses, the company's shares have gained 11.12%
in the previous three months, outperforming the S&P 500, which has advanced
7.81% during the same period. Additionally, Pharmacyclics Inc.'s stock is
trading above its 200-day moving average of $99.52. Register now to download
free research on PCYC at:

http://www.AAAResearchReports.com/PCYC112113.pdf

Shares in United Therapeutics Corp. oscillated between $91.08 and $93.16
before ending Wednesday's session 1.00% lower at $91.64. A total of 0.28
million shares were traded, which is below the daily average volume of 0.48
million. Despite Wednesday's pullback, the company's shares have gained 11.12%
in the last one month and 27.14% in the previous three months, outperforming
the S&P 500, which has gained 2.11% and 7.81% during the respective periods.
Moreover, United Therapeutics Corp.'s stock is trading above its 50-day and
200-day moving averages of $83.86 and $70.13, respectively. A free report on
UTHR can be accessed by registering at:

http://www.AAAResearchReports.com/UTHR112113.pdf

On Wednesday, shares in Impax Laboratories Inc. advanced to end the day at
$23.14, which is 1.40% higher than the previous day's closing price of $22.82.
The company's shares oscillated between $22.90 and $23.30 during the trading
session. A total of 0.33 million shares were traded, which is below the daily
average volume of 0.44 million. The company's shares have gained 12.77% in the
last one month and 10.82% in the previous three months, outperforming the S&P
500, which has gained 2.11% and 7.81% during the respective periods. Further,
Impax Laboratories Inc.'s stock is trading near its 52-week high of $23.74 and
above its 50-day and 200-day moving averages of $20.89 and $19.30,
respectively. Register with AAA Research Reports and download research on IPXL
for free at:

http://www.AAAResearchReports.com/IPXL112113.pdf

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

www.AAAresearchreports.com

SOURCE AAA Research Reports

Contact: Phone #: +1(646)396-9126, Contact Name: Peter F. Jones Email ID:
info@aaaresearchreports.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement